Thromboembolic diseases of childhood

被引：22

作者：

Revel-Vilk, S

Massicotte, P

机构：

[1] Univ Toronto, Hosp Sick Children, Pediat Thrombosis & Haemostasis Program, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada

[2] Univ Toronto, Hosp Sick Children, Populat Hlth Sci, Toronto, ON M5G 1X8, Canada

来源：

BLOOD REVIEWS | 2003年 / 17卷 / 01期

关键词：

thromboembolic events; children; risk factors; diagnosis; treatment;

D O I：

10.1016/S0268-960X(02)00007-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Over the last decade, pediatric thrombophilia programs have emerged around the world as a new discipline in pediatric hematology. These programs specialize in the diagnosis, prevention and treatment of children with thromboembolic events (TEs) in both the venous and arterial systems. The need for separate pediatric programs has been discussed previously. (J Pediatr Hematol Oncol 1997; 19: 7-22.) The following article will update previous reviews (Hematol Oncol Clin North Am 1998; 12: 1283-1312; Thromb Haemost 1997; 78: 715-725) and will concentrate on three aspects: (1) The risk factors for acquiring TEs; (2) The confirmatory diagnostic tests used in children with TEs; and (3) The different antithrombotic agents used for prevention and treatment. The current knowledge in respect to the above points is only the "tip of the iceberg". Well-designed prospective trials are required to establish the contribution of congenital prothrombotic disorders, appropriate diagnostic strategies, and optimal therapy for children with TEs. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：1 / 6

页数：6

共 97 条

[31] USE OF HEPARINIZATION TO PREVENT ARTERIAL THROMBOSIS AFTER PERCUTANEOUS CARDIAC-CATHETERIZATION IN CHILDREN [J].

FREED, MD ;

KEANE, JF ;

ROSENTHAL, A .

CIRCULATION, 1974, 50 (03) :565-569

[32] Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients [J].

Gaustadnes, M ;

Rüdiger, N ;

Moller, J ;

Rasmussen, K ;

Larsen, TB ;

Ingerslev, J .

BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 (05) :251-259

[33] Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children [J].

Gupta, AA ;

Leaker, M ;

Andrew, M ;

Massicotte, P ;

Liu, L ;

Benson, LN ;

McCrindle, BW .

JOURNAL OF PEDIATRICS, 2001, 139 (05) :682-688

[34] Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease [J].

Hagstrom, JN ;

Walter, J ;

Bluebond-Langner, R ;

Amatniek, JC ;

Manno, CS ;

High, KA .

JOURNAL OF PEDIATRICS, 1998, 133 (06) :777-781

[35] Abdominal venous thrombosis in neonates and infants:: role of prothrombotic risk factors -: a multicentre case-control study [J].

Heller, C ;

Schobess, R ;

Kurnik, K ;

Junker, R ;

Günther, G ;

Kreuz, W ;

Nowak-Göttl, U .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (02) :534-539

[36] Prothrombotic risk factors in childhood stroke and venous thrombosis [J].

Heller, C ;

Becker, S ;

Scharrer, I ;

Kreuz, W .

EUROPEAN JOURNAL OF PEDIATRICS, 1999, 158 (Suppl 3) :S117-S121

[37] Coagulation-associated complications of indwelling arterial and central venous catheters during heparin prophylaxis - a prospective study [J].

Hentschel, R ;

Wiescholek, U ;

von Lengerke, J ;

Harms, E ;

Jorch, G .

EUROPEAN JOURNAL OF PEDIATRICS, 1999, 158 (Suppl 3) :S126-S129

[38] Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range [J].

Hirsh, J ;

Dalen, JE ;

Anderson, DR ;

Poller, L ;

Bussey, H ;

Ansell, J ;

Deykin, D .

CHEST, 2001, 119 (01) :8S-21S

[39] Heparin and low-molecular-weight heparin - Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety [J].

Hirsh, J ;

Warkentin, TE ;

Shaughnessy, SG ;

Anand, SS ;

Halperin, JL ;

Raschke, R ;

Granger, C ;

Ohman, EM ;

Dalen, JE .

CHEST, 2001, 119 (01) :64S-94S

[40]

HOOSHANG T, 1990, RADIOLOGY, V176, P728

← 1 2 3 4 5 6 7 8 9 10 →